drugset / Trial / NCT02864498

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

NCT02864498 ↗

Phase 2 Completed 321 enrolled DS Biopharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether orally administered DS107 (1g and 2g doses) is effective in the treatment of moderate to severe atopic dermatitis. Oral DS107 capsules will be administered for 8 weeks and will be compared against placebo. The study will enroll approximately 300 subjects.

Timeline

Start
2017-01
Primary completion
2018-06
Completion
2018-06

Outcome

Missed primary endpoint

registry analysis (superiority test); 1g DS107 vs Placebo; p = 0.5570; General Linear Model NCT02864498 ↗

registry analysis (superiority test); 2g DS107 vs Placebo; p = 0.8774; General Linear Model NCT02864498 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject DIHOMO-GAMMA-LINOLENIC ACID Small molecule 1 g Oral
Subject DIHOMO-GAMMA-LINOLENIC ACID Small molecule 2 g Oral

Indications